Amgen Inc. vs Oracle Corporation: Strategic Comparison

This in-depth comparison examines Amgen Inc. and Oracle Corporation across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Amgen Inc. on its own, evaluating Oracle Corporation, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Amgen Inc. and Oracle Corporation is widest.

On the headline numbers, Amgen Inc. reports annual revenue of $36.8B against $67.4B for Oracle Corporation, while their respective market capitalizations stand at $228.2B and $393.6B. Both Amgen Inc. and Oracle Corporation are headquartered in United States, so they compete in a shared home market and regulatory environment.

Amgen Inc.: Amgen is one of the companies that created the biotechnology industry. Instead of synthesizing small-molecule drugs, it engineers living cells to make complex proteins, an approach it first commercialized with Epogen in 1989. Based in Thousand Oaks, California, it is best known for medicines in bone health, inflammation, cardiovascular disease and kidney disease, and since the 2023 Horizon acquisition in rare disease. Fiscal 2025 revenue was US$36.8 billion across a portfolio in which 14 products each sold more than US$1 billion, although several of the older brands are now losing both price and volume.

Oracle Corporation: Oracle is best known for Oracle Database, the relational database behind many bank, airline, telecom and government systems. Over four decades it added middleware (BEA), applications (PeopleSoft, Siebel, Hyperion, NetSuite), Java and hardware (Sun Microsystems) and healthcare records (Cerner). The company moved its headquarters from Redwood Shores, California to Austin, Texas in December 2020. Since 2023 its identity has shifted again, toward Oracle Cloud Infrastructure as a landlord for AI model training.

Amgen Inc. and Oracle Corporation pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Amgen Inc. and Oracle Corporation.

Amgen Inc. business model: Amgen operates a high-risk, high-reward biopharmaceutical business model. It spends heavily on research to discover and engineer new biologic drugs: US$7.3 billion in fiscal 2025, or 20.7% of product sales. Once a drug is approved by the FDA, Amgen secures a patent, granting them a temporary monopoly to sell the drug at a premium price. Because biologic drugs are grown from living cells rather than chemically synthesized, they are much harder for competitors to copy, resulting in slightly longer and more defensible monopolies than traditional pills.

Oracle Corporation business model: Oracle sells to businesses and governments, not consumers. Its largest revenue line is cloud services and license support: customers pay recurring fees for OCI compute, storage, GPUs and database services, for Fusion Cloud ERP, HCM, SCM and NetSuite subscriptions, and for annual support on licensed Oracle Database and middleware. Smaller lines are new cloud and on-premise licenses (Q1 FY2027 software revenue was $5.5 billion, down 3% as customers migrate to cloud), services ($1.4 billion in Q1 FY2027) and hardware ($0.8 billion). OCI is now the growth engine: in Q1 FY2027 infrastructure revenue was $7.4 billion against $4.2 billion for cloud applications.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Amgen Inc. stack up against those of Oracle Corporation.

Amgen Inc. competitive advantage: Amgen's main competitive advantage is experience making complex biologics at commercial scale, which it has done continuously since Epogen launched in 1989. Producing a glycosylated protein or a monoclonal antibody to a consistent specification requires validated facilities, process know-how and a regulatory record that take years to build, which is also why the company can turn the same capability toward biosimilars of competitor products. Its balance sheet lets it buy late-stage assets rather than rely only on internal discovery: Onyx, Otezla, Five Prime, ChemoCentryx and Horizon together cost about US$57 billion between 2013 and 2023.

Oracle Corporation competitive advantage: Oracle's edge comes from its installed base. Oracle Database runs core financial, telecom and government systems, and moving those workloads is slow, expensive and risky, which keeps support revenue recurring. OCI adds a price-performance pitch built on bare-metal servers and RDMA networking for large GPU clusters, and Oracle can offer the same database inside rival clouds. Its weaknesses are a smaller cloud services catalog than AWS or Azure and a long record of customer complaints about licensing audits.

Future prospects matter as much as current results. The growth strategies below explain how Amgen Inc. and Oracle Corporation each plan to expand from here.

Amgen Inc. growth strategy: Amgen's growth plan has two parts: scale the newer medicines and buy what the pipeline does not supply. Recent launches and acquired products drove the 10% revenue growth in fiscal 2025, with Tezspire up 52% to US$1.48 billion, Repatha up 36% to US$3.02 billion, Evenity up 34% to US$2.10 billion, Uplizna up 73% to US$655 million and Imdelltra reaching US$627 million in its second year. The company is pushing into obesity with MariTide, now in six Phase 3 MARITIME studies, and runs a biosimilars business that produced about US$3.0 billion of fiscal 2025 sales across Pavblu, Mvasi, Amjevita and Wezlana.

Oracle Corporation growth strategy: Oracle's growth plan rests on renting AI training and inference capacity at very large scale. It is building data centers for OpenAI under the Stargate program (a partnership OpenAI describes as over $300 billion across five years and up to 4.5 gigawatts), and it also serves xAI, Meta, NVIDIA and AMD workloads. In Q1 FY2027 it booked more than $30 billion of new AI cloud contracts, delivered 850 MW of additional capacity and over 300,000 GPUs. Alongside that, Oracle runs its database inside Azure, AWS and Google Cloud data centers (multicloud database), pushes Fusion and NetSuite SaaS, and is rebuilding Oracle Health, the former Cerner business it bought for $28.3 billion in 2022.

A closer look at the financial trajectory of Amgen Inc. and Oracle Corporation rounds out the comparison.

Amgen Inc.: Amgen is a cash-generative business with high product gross margins. In fiscal 2025 it reported US$36.8 billion of total revenues, US$7.7 billion of GAAP net income, a 25.8% GAAP operating margin, US$8.1 billion of free cash flow and US$5.1 billion of dividends paid. Its results used to depend on a few large franchises, first Epogen and Aranesp, then Enbrel. As those matured Amgen bought revenue instead: Onyx in 2013, Otezla in 2019 and Horizon Therapeutics for US$27.8 billion in 2023. That last deal is also the main reason for the balance sheet it now carries, with US$54.6 billion of debt outstanding at December 31, 2025, debt leverage of about 3.2 times EBITDA and US$2.8 billion of net interest expense in fiscal 2025.

Oracle Corporation: Oracle's revenue grew from $39.1 billion in FY2020 to $57.4 billion in FY2025 and $67.36 billion in FY2026, when net income was $17.09 billion. Growth is now driven by cloud: Q1 FY2027 cloud revenue (IaaS plus SaaS) was $11.6 billion, up 62%, and operating cash flow was a record $23 billion for the quarter. The other side of the ledger is capex. FY2026 capital spending of $55.7 billion pushed free cash flow negative, and Oracle has funded the gap with bond issuance and equity sales. Management guides to at least $90 billion of FY2027 revenue and non-GAAP EPS of $8.10.